Two closely related cationic bis-N-heterocyclic carbene (NHC) gold(I) complexes show sharply divergent behavior in cancer cells: Au3BC (acridine-functionalized NHCs) potently inhibits thioredoxin reductase 1 (TrxR1) yet does not kill hepatocellular carcinoma (Huh7) or triple-negative breast cancer (MDA-MB-231) cells, in part because the cells mount a pro-survival response (RAD51 upregulation and autophagic flux blockage); Au4BC (4,5-bis(4-methoxyphenyl)imidazol-2-ylidene NHCs) barely inhibits TrxR1 yet kills both cell lines through reactive oxygen species (ROS) production, DNA damage, and apoptosis. The direct molecular targets of Au4BC — the proteins (or alternative chemical mechanisms) whose engagement produces ROS, DNA damage, and cell death without TrxR1 inhibition — have never been identified, and the structural and mechanistic determinants that switch a bis-NHC gold(I) complex between TrxR1-dependent and TrxR1-independent modes of action remain unmapped. This record poses the target-identification and mechanism question for Au4BC, whose field-level openness a 2025 Chemical Society Reviews assessment of Au NHC anticancer agents confirms: it lists the precise modes of action of these complexes, and mechanistic pathways beyond thioredoxin reductase inhibition, among the field's unresolved challenges.

Background

Gold(I) complexes are the most advanced class of non-platinum anticancer metallodrugs. The anti-rheumatic drug auranofin, whose anticancer activity is being repurposed clinically, acts by inhibiting thioredoxin reductase (TrxR) — a selenocysteine-containing enzyme that, together with its substrate thioredoxin (Trx), controls cellular redox homeostasis and is frequently overexpressed in tumors. N-heterocyclic carbene (NHC) ligands — strong sigma-donor carbon ligands that bind gold(I) tightly and resist ligand exchange — have become the scaffold of choice for medicinal gold chemistry because they stabilize the Au(I) center while allowing systematic variation of the ligand periphery. Many cytotoxic NHC-gold(I) complexes are indeed potent TrxR inhibitors, and TrxR inhibition is commonly assumed to be their mechanism of action.

Two cationic bis-NHC gold(I) complexes challenge that assumption. Au3BC, bis[1-methyl-3-acridineimidazolin-2-ylidene]gold(I) tetrafluoroborate, carries an acridine (a planar, DNA-intercalating heteroaromatic) as a wingtip group; Au4BC, bis[1,3-diethyl-4,5-bis(4-methoxyphenyl)imidazol-2-ylidene]gold(I) bromide, carries bulky 4-methoxyphenyl substituents at the 4,5-positions of the imidazolylidene ring. Au4BC was first synthesized by Liu et al. in 2012, who found growth-inhibitory potency more than tenfold higher than cisplatin against breast and colon cancer cell lines while explicitly excluding TrxR, the estrogen receptor, and cyclooxygenases from its mode of action. Au3BC was reported by Visbal et al. in 2016 to localize mainly in lysosomes of lung and pancreatic cancer cells, its biological targets likewise unidentified. The molecular targets of neither compound were ever established.

Augello et al. (2023) compared the two compounds head-to-head in Huh7 hepatocellular carcinoma (HCC) cells and MDA-MB-231 triple-negative breast cancer (TNBC) cells. Au3BC inhibited purified and cellular TrxR1 in a dose-dependent manner (assayed by reduction of DTNB, 5,5-dithio-bis(2-nitrobenzoic acid), a standard chromogenic substrate for thiol reductases) but did not reduce cell viability up to 20 µM; it induced neither apoptosis (no cleavage of PARP1, poly(ADP-ribose) polymerase-1, an enzyme proteolytically cleaved during apoptosis) nor DNA damage (no γ-H2AX, the phosphorylated histone variant H2AX marking DNA double-strand breaks), but instead upregulated RAD51 — the recombinase that mediates homologous-recombination repair of DNA double-strand breaks — and increased p62/SQSTM1, an autophagy receptor normally degraded as autophagy proceeds, so that its accumulation signals blocked autophagic flux. RAD51 knockdown by small interfering RNA sensitized Huh7 cells to Au3BC (reducing viability by 15% at 2.5 µM and by 30% at 20 µM relative to control siRNA), restoring DNA damage, apoptosis, and completion of the autophagic process, which shows the upregulated RAD51 is part of an active pro-survival escape response rather than incidental damage, although the partial sensitization indicates that this response accounts for only part of Au3BC's non-cytotoxicity. Conversely, Au4BC did not inhibit TrxR1 (inactive up to 1.6 µM; IC50 above 10 µM in earlier reports) but killed both cell lines, raising intracellular ROS (H2DCFDA probe, a cell-permeable dye that becomes fluorescent upon oxidation), inducing γ-H2AX with RAD51 downregulation, activating autophagic flux, and triggering apoptosis; the ROS scavenger N-acetyl-L-cysteine almost fully rescued viability, tying Au4BC's lethality to ROS generation. Neither compound modified Trx1 enzymatic activity.

The paper's conclusion is explicit: TrxR1 inhibition alone is not sufficient for cell death, and Au4BC acts on 'other targets, whose identification will help to develop new potential anticancer therapies.' How TrxR1 inhibition couples to RAD51 upregulation and autophagy blockage in the Au3BC-treated cells is equally unexplained. A mechanistic decoupling of TrxR inhibitory potency from cytotoxicity has since been recognized as a recurring confound in gold metallodrug development: a 2025 Chemical Society Reviews survey of Au NHC anticancer agents states that 'challenges concerning revealing the precise modes of action are discussed' and that 'mechanistic pathways beyond the inhibition of thioredoxin reductase are highlighted' as the field's frontier (abstract; the full text is paywalled). Proteome-scale target deconvolution of the kind demonstrated for auranofin by redox proteome analysis (Chiappetta et al. 2022) has not been applied to NHC-gold complexes such as Au4BC. Chemical complications are known for this compound family: the Gust group showed that closely related 4,5-diaryl bis-NHC gold(I) complexes undergo ligand scrambling (redistribution of the NHC ligands between gold centers, converting mono-NHC to bis-NHC species) and react with glutathione in cell culture medium, so the active intracellular species of Au4BC is itself not fully characterized.

Problem Statement

Identify the direct molecular targets of the bis-NHC gold(I) complex Au4BC — bis[1,3-diethyl-4,5-bis(4-methoxyphenyl)imidazol-2-ylidene]gold(I) bromide — in cancer cells, and establish how their engagement produces its cytotoxicity, which is independent of thioredoxin reductase 1 (TrxR1, the selenocysteine-containing cellular redox enzyme): the intracellular generation of reactive oxygen species (ROS), DNA double-strand damage (marked by induction of γ-H2AX, the phosphorylated histone variant H2AX, with downregulation of RAD51, the recombinase mediating homologous-recombination repair), activation of autophagic flux (completion of autophagic degradation), and apoptosis (marked by cleavage of poly(ADP-ribose) polymerase-1, PARP1) observed in Huh7 hepatocellular carcinoma and MDA-MB-231 triple-negative breast cancer cells, whose viability is rescued by the ROS scavenger N-acetyl-L-cysteine. The question is motivated by the head-to-head contrast with the companion complex Au3BC — bis[1-methyl-3-acridineimidazolin-2-ylidene]gold(I) tetrafluoroborate — which inhibits TrxR1 in the same cells yet is not cytotoxic, mounting a partially protective pro-survival response (RAD51 upregulation and autophagic-flux blockage). An answer may take either of two independently sufficient forms: (i) specific protein targets, together with a mechanistic account of how their engagement produces the observed phenotypes; or (ii) a non-protein-target chemical mechanism for Au4BC itself (for example, an intracellular speciation or degradation pathway of the complex that generates the observed redox and DNA-damage phenotypes). In either form, a reasoned, cited proposal that names the candidate target(s) or mechanism and supplies an explicit experimental validation strategy is sufficient; wet-lab validation is not required.

References

  1. Augello G, Azzolina A, Rossi F, Prencipe F, Mangiatordi GF, Saviano M, Ronga L, Cervello M, Tesauro D. 'New Insights into the Behavior of NHC-Gold Complexes in Cancer Cells.' Pharmaceutics 2023, 15(2), 466. DOI 10.3390/pharmaceutics15020466. https://doi.org/10.3390/pharmaceutics15020466
  2. Liu W, Bensdorf K, Proetto M, Hagenbach A, Abram U, Gust R. 'Synthesis, Characterization, and in Vitro Studies of Bis[1,3-diethyl-4,5-diarylimidazol-2-ylidene]gold(I/III) Complexes.' Journal of Medicinal Chemistry 2012, 55(8), 3713-3724. DOI 10.1021/jm3000196. https://doi.org/10.1021/jm3000196
  3. Visbal R, Fernandez-Moreira V, Marzo I, Laguna A, Gimeno MC. 'Cytotoxicity and biodistribution studies of luminescent Au(I) and Ag(I) N-heterocyclic carbenes. Searching for new biological targets.' Dalton Transactions 2016, 45(38), 15026-15033. DOI 10.1039/c6dt02878k. https://doi.org/10.1039/c6dt02878k
  4. Bernabeu De Maria M, Matczuk M, Tesauro D, Saviano M, Sikorski J, Chiappetta G, Godin S, Szpunar J, Lobinski R, Ronga L. 'Study of metalation of thioredoxin by gold(I) therapeutic compounds using combined liquid chromatography/capillary electrophoresis with inductively coupled plasma/electrospray MS/MS detection.' Analytical and Bioanalytical Chemistry 2024, 416(11), 2819-2833. DOI 10.1007/s00216-024-05140-z. https://doi.org/10.1007/s00216-024-05140-z
  5. Kapitza P, Scherfler A, Salcher S, Sopper S, Cziferszky M, Wurst K, Gust R. 'Reaction Behavior of [1,3-Diethyl-4,5-diphenyl-1H-imidazol-2-ylidene] Containing Gold(I/III) Complexes against Ingredients of the Cell Culture Medium and the Meaning on the Potential Use for Cancer Eradication Therapy.' Journal of Medicinal Chemistry 2023, 66(12), 8238-8250. DOI 10.1021/acs.jmedchem.3c00589. https://doi.org/10.1021/acs.jmedchem.3c00589
  6. Scherfler A, Schwaiger S, Wurst K, Kircher B, Baecker D, Gust R. 'Introduction of 1,3-diethyl-4,5-diphenyl-4,5-dihydro-1H-imidazol-2-ylidene as new ligand for the design of antitumor-active (NHC)gold(I) complexes: An approach to reduce ligand scrambling and to increase tumor cell selectivity.' European Journal of Medicinal Chemistry 2025, 299, 117919. DOI 10.1016/j.ejmech.2025.117919. https://doi.org/10.1016/j.ejmech.2025.117919
  7. Hoffmann ME, Kuehn FE. 'Au NHC complexes as anticancer agents: milestones, strategies and future developments.' Chemical Society Reviews 2025, 54(22), 10326-10343. DOI 10.1039/d5cs00924c. https://doi.org/10.1039/d5cs00924c
  8. Mertens RT, Gukathasan S, Arojojoye AS, Olelewe C, Awuah SG. 'Next Generation Gold Drugs and Probes: Chemistry and Biomedical Applications.' Chemical Reviews 2023, 123(10), 6612-6667. DOI 10.1021/acs.chemrev.2c00649. https://doi.org/10.1021/acs.chemrev.2c00649
  9. Zhao Q, Han B, Peng C, Zhang N, Huang W, He G, Li JL. 'A promising future of metal-N-heterocyclic carbene complexes in medicinal chemistry: The emerging bioorganometallic antitumor agents.' Medicinal Research Reviews 2024, 44(5), 2194-2235. DOI 10.1002/med.22039. https://doi.org/10.1002/med.22039
  10. Bernal G, Aquea G, Ramirez-Rivera S. 'Metal-based molecules in the treatment of cancer: From bench to bedside.' Oncology Research 2025, 33(4), 759-779. DOI 10.32604/or.2024.057019. https://doi.org/10.32604/or.2024.057019
  11. Ansari E, Kumar R, Ratnam A. 'Gold-NHC complexes: from synthetic aspects to anti-cancer activity.' Dalton Transactions 2025, 54(19), 7553-7601. DOI 10.1039/d5dt00118h. https://doi.org/10.1039/d5dt00118h
  12. Begum A, PN N, Kumar P, Telukutla SR, Ojha R, Plebanski M, Bhargava SK. 'Nature-Inspired Gold(I) Complexes as Anticancer Agents: Ligand Design, Structure-Activity Relationships, and Mechanisms.' Cancers 2026, 18(4), 631. DOI 10.3390/cancers18040631. https://doi.org/10.3390/cancers18040631
  13. Chiappetta G, Gamberi T, Faienza F, Limaj X, Rizza S, Messori L, Filomeni G, Modesti A, Vinh J. 'Redox proteome analysis of auranofin exposed ovarian cancer cells (A2780).' Redox Biology 2022, 52, 102294. DOI 10.1016/j.redox.2022.102294. https://doi.org/10.1016/j.redox.2022.102294